An Open Clinical Study to Evaluate the Efficacy of Shirobasti and Nasya with and without Levodopa in the Management of Kampavata w.s.r. to Parkinson’s Disease (PD)
Background: Kampavata (Parkinson’s disease), considered as Vata Nanatamaja disorder, is the most common progressive neurodegenerative disorder characterized by bradykinesia, resting tremors, muscular rigidity, shuffling gait and flexed posture accompanied by a variety of non-motor symptoms, including autonomic, sensory, sleep, cognitive and psychiatric disturbances. Aim and Objectives: To study the effect of Shirobasti and Nasya in the management of Kampavata (PD) with levodopa and without levodopa. Materials and Methods: The present clinical trial was an open label, interventional prospective research, conducted on 30 subjects of Kampavata (PD) who had fulfilled the inclusion criteria. Subjects were divided into two groups, having 15 cases in each group and treated with Shirobasti and Nasya with Ksheerbala Taila for 14 days. Patients of Group A were allowed to continue levodopa in a fixed dose during the trial whereas in Group B, levodopa was not given to the subjects. Total duration of study was 45 days. Assessment was done on the basis of Unified Parkinson Disease Rating Scale (UPDRS) scale (modified) before, after the treatment and after follow-up. Ethical clearance and written consent was obtained. A detailed case record form and patient information sheet was prepared for the study. Results: The comparative effect of both the procedures showed more significant results in Group B (without levodopa) than Group A (with levodopa). Conclusion: In Group A, significant results were found in Stambha, Gativikriti, Avanamana, ADL, Motor Examination, Schwab and England ADL scale and in Group B, significant results were found in Kampa, Chestasanga, Vakavikriti, Mentation, Behaviour and mood, Modified Hoehn and Yahr Staging. Shirobasti and Nasya showed improvements in the signs and symptoms of Kampavata (PD) in both the groups. Both the procedures were efficacious in reducing Activities of Daily Living, thereby improving quality of life in both the groups.
